The discovery of the Universal Receptive System introduces a new understanding of how cells sense their environment, store information, and change their behavior.
At the center of this system are TezR receptors, extracellular DNA- and RNA-based regulatory structures located on the cell surface along with integrases and recombinases. Unlike traditional receptor systems, TezRs are not limited to one signaling pathway. They appear to regulate broad cellular functions, including environmental sensing, cellular memory, adaptation, immune activity, biofilm formation, and antibiotic response.
This biology helps explain why cells and microorganisms often behave differently in real disease than they do under simplified laboratory conditions. Their behavior is shaped not only by their genome, but also by previous exposures, environmental stress, microbial interactions, and preserved cell memory.
By modulating the Universal Receptive System, it becomes possible to change cellular function without genetic engineering. This creates a new therapeutic opportunity: cells can be reprogrammed through their receptive system to acquire new biological activity.
This principle forms the foundation of our platforms, including AtbFinder and SL-28. AtbFinder applies this biology to preserve microbial community behavior and identify effective antibiotics under conditions that mirror the patient’s site of infection. SL-28 applies the same biological principle to immune cells, reprogramming donor leukocytes ex vivo to enhance their antimicrobial and anticancer activity.
Together, these technologies represent a new biological paradigm: treating disease by understanding and controlling how cells receive, remember, and respond to information.
References
- Tetz V, Tetz G. “Novel prokaryotic system employing previously unknown nucleic acids-based receptors.” Microbial Cell Factories. 2022;21:1–33. DOI: 10.1186/s12934-022-01923-0.
- Tetz V, Tetz G. “Novel Cell Receptor System of Eukaryotes Formed by Previously Unknown Nucleic Acid-Based Receptors.” DNA. 2022.
- Tetz G, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz V. “Universal receptive system as a novel regulator of transcriptomic activity of Staphylococcus aureus.” Microbial Cell Factories. 2025;24:1. DOI: 10.1186/s12934-024-02637-1.
- Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. “Previously unknown regulatory role of extracellular RNA on bacterial directional migration.” bioRxiv / PubMed preprint record. 2024.
- Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. “Regulating white blood cell activity through the novel universal receptive system.” Scientific Reports. 2025.
- Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. “The Universal Receptive System acts as a novel regulator in the production of antimicrobial and anticancer bioactive compounds by white blood cells.” Journal of Leukocyte Biology. 2025.
- Tetz V, Kardava K, Vecherkovskaya M, Khodadadi-Jamayran A, Tsirigos A, Tetz G. “Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient With Advanced Prostate Cancer: A Case Report.” ImmunoTargets and Therapy. 2025.
- “Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report.” Frontiers in Oncology. 2025.
- Tetz G, Tetz V. “Evaluation of a New Culture-Based AtbFinder Test-System Employing a Novel Nutrient Medium for the Selection of Optimal Antibiotics for Critically Ill Patients with Polymicrobial Infections within 4 h.” Microorganisms. 2021;9(5):990. DOI: 10.3390/microorganisms9050990.
- Tetz G, Tetz V, et al. “AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis.” Journal of Clinical Microbiology. 2023. DOI: 10.1128/jcm.01558-22.
- ClinicalTrials.gov / ICH GCP Registry: “Clinical Performance of the AtbFinder® Test System for Selection of Antibiotic Therapy in Persons With Cystic Fibrosis.” NCT05584982.
- “Treatment of chronic relapsing urinary tract infection with antibiotics selected using AtbFinder: a case report.”